Hidden Killer: Huntington's Disease Cases Rise as Thousands Remain Undiagnosed

A troubling rise in diagnosed cases of Huntington's Disease, a devastating condition often described as a cruel blend of dementia and motor neurone disease, is alarming experts globally. While not a mysterious doubling, better diagnostic tools are revealing more affected individuals, with thousands still unknowingly living with this inherited and progressive brain disorder. This increased recognition underscores the urgent need for wider screening and advanced therapies before symptoms become irreversible. This rise in identified cases isn't necessarily a sudden explosion in new patients but rather a reflection of advanced genetic testing and improved awareness bringing previously hidden diagnoses to light. Huntington's is caused by a faulty HTT gene with too many CAG trinucleotide repeats, leading to toxic huntingtin protein that damages brain cells. Recent breakthroughs in 2025 and 2026 offer glimmers of hope: researchers have unveiled new insights into how the toxic protein spreads via 'tunneling nanotubes' and identified new biomarkers for early detection. Meanwhile, promising gene therapy candidates like uniQure's AMT-130 and Skyhawk's SKY-0515 are showing encouraging results in clinical trials, aiming to tackle the disease at its genetic root. Looking ahead, the focus is sharply on accelerating these experimental treatments and making predictive genetic testing more accessible globally. Companies like Latus Bio are moving forward with new gene therapy applications to the FDA, targeting the very mechanism of gene expansion. The goal is to move beyond just managing symptoms to truly modifying the disease, potentially halting its progression before severe brain damage occurs and offering a lifeline to countless families living under the shadow of this brutal illness.